Search

Your search keyword '"Byrne, Christopher D."' showing total 1,698 results
Start Over Author "Byrne, Christopher D."
1,698 results on '"Byrne, Christopher D."'

1. Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals

Author

Au, Kahei, Zheng, Ming-Hua, Lee, Wei-Jei, Ghanem, Omar M., Mahawar, Kamal, Shabbir, Asim, le Roux, Carel W., Targher, Giovanni, Byrne, Christopher D., Yilmaz, Yusuf, Valenti, Luca, Sebastiani, Giada, Treeprasertsuk, Sombat, Hui, Hannah Xiaoyan, Sakran, Nasser, Neto, Manoel Galvao, Kermansaravi, Mohammad, Kow, Lilian, Seki, Yosuke, Tham, Kwang Wei, Dang, Jerry, Cohen, Ricardo V., Stier, Christine, AlSabah, Salman, Oviedo, Rodolfo J., Chiappetta, Sonja, Parmar, Chetan, and Yang, Wah

Published
2024
Full Text
View/download PDF

3. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

Author

Zhang, Huai, Targher, Giovanni, Byrne, Christopher D., Kim, Seung Up, Wong, Vincent Wai-Sun, Valenti, Luca, Glickman, Myer, Ponce, Jaime, Mantzoros, Christos S., Crespo, Javier, Gronbaek, Henning, Yang, Wah, Eslam, Mohammed, Wong, Robert J., Machado, Mariana Verdelho, Yu, Ming-Lung, Ghanem, Omar M., Okanoue, Takeshi, Liu, Jun-Feng, Lee, Yong-ho, Xu, Xiao-Yuan, Pan, Qiuwei, Sui, Meili, Lonardo, Amedeo, Yilmaz, Yusuf, Zhu, Li-Yong, Moreno, Christophe, Miele, Luca, Lupsor-Platon, Monica, Zhao, Lei, LaMasters, Teresa LeAnn, Gish, Robert G., Zhang, Huijie, Nedelcu, Marius, Chan, Wah Kheong, Xia, Ming-Feng, Bril, Fernando, Shi, Jun-Ping, Datz, Christian, Romeo, Stefano, Sun, Jian, Liu, Dan, Sookoian, Silvia, Mao, Yi-Min, Méndez-Sánchez, Nahum, Wang, Xiao-Yan, Pyrsopoulos, Nikolaos T., Fan, Jian-Gao, Fouad, Yasser, Sun, Dan-Qin, Giannini, Cosimo, Chai, Jin, Xia, Ze-Feng, Jun, Dae Won, Li, Guo-Jing, Treeprasertsuk, Sombat, Li, Ying-Xu, Cheung, Tan To, Zhang, Faming, Goh, George Boon-Bee, Furuhashi, Masato, Seto, Wai-Kay, Huang, Hui, Di Sessa, Anna, Li, Qing-Hong, Cholongitas, Evangelos, Zhang, Le, Silveira, Themis Reverbel, Sebastiani, Giada, Adams, Leon A., Chen, Wei, Qi, Xiaolong, Rankovic, Ivan, De Ledinghen, Victor, Lv, Wen-Jie, Hamaguchi, Masahide, Kassir, Radwan, Müller-Wieland, Dirk, Romero-Gomez, Manuel, Xu, Ying, Xu, Yi-Cong, Chen, Shi-Yao, Kermansaravi, Mohammad, Kuchay, Mohammad Shafi, Lefere, Sander, Parmar, Chetan, Lip, Gregory Y. H., Liu, Chun-Jen, Åberg, Fredrik, Lau, George, George, Jacob, Sarin, Shiv Kumar, Zhou, Jing-Ya, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

4. Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: a prospective study

Author

Mantovani, Alessandro, Busti, Fabiana, Borella, Nicolò, Scoccia, Enrico, Pecoraro, Barbara, Sani, Elena, Morandin, Riccardo, Csermely, Alessandro, Piasentin, Daniele, Grespan, Elisabetta, Castagna, Annalisa, Bilson, Josh, Byrne, Christopher D., Valenti, Luca, Girelli, Domenico, and Targher, Giovanni

Published
2024
Full Text
View/download PDF

7. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E, Lazarus, Jeffrey V, Ratziu, Vlad, Francque, Sven M, Sanyal, Arun J, Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F, Anstee, Quentin M, Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D, Narro, Graciela E Castro, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R, Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D, Harrison, Stephen A, Kim, Seung Up, Koot, Bart G, Korenjak, Marko, Kowdley, Kris V, Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R, Powell, Elisabeth E, Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C, Spearman, C Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B, Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, Newsome, Philip N, and group, NAFLD Nomenclature consensus

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Digestive Diseases, Clinical Research, Hepatitis, Chronic Liver Disease and Cirrhosis, Substance Misuse, Oral and gastrointestinal, Good Health and Well Being, Female, Male, Humans, Non-alcoholic Fatty Liver Disease, Delphi Technique, Ethanol, Consensus, Hepatomegaly, NAFLD Nomenclature consensus group, ALD, Delphi, MASH, MASLD, Met-ALD, NAFLD, alcohol, metabolic, nomenclature, stigma, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.

Published
2023

8. Secondary bile acids improve risk prediction for non‐invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease

Author

Liu, A‐Na, Xu, Cui‐Fang, Liu, Ya‐Ru, Sun, Dan‐Qin, Jiang, Ling, Tang, Liang‐Jie, Zhu, Pei‐Wu, Chen, Sui‐Dan, Liu, Wen‐Yue, Wang, Xiao‐Dong, Targher, Giovanni, Byrne, Christopher D, Wong, Vincent Wai‐Sun, Fu, Junfen, Su, Ming‐Ming, Loomba, Rohit, Zheng, Ming‐Hua, and Ni, Yan

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Hepatitis, Liver Disease, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Women's Health, Clinical Research, Obesity, Oral and gastrointestinal, Good Health and Well Being, Adult, Male, Humans, Female, Non-alcoholic Fatty Liver Disease, Bile Acids and Salts, Liver Cirrhosis, Inflammation, Biomarkers, Liver, liver fibrosis, nonalcoholic fatty liver disease, risk prediction, secondary bile acids, Pharmacology and Pharmaceutical Sciences, Gastroenterology & Hepatology, Clinical sciences, Pharmacology and pharmaceutical sciences
Abstract

BackgroundDysregulated bile acid (BA) metabolism has been linked to steatosis, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).AimTo determine whether circulating BA levels accurately stage liver fibrosis in NAFLD.MethodsWe recruited 550 Chinese adults with biopsy-proven NAFLD and varying levels of fibrosis. Ultra-performance liquid chromatography coupled with tandem mass spectrometry was performed to quantify 38 serum BAs.ResultsCompared to those without fibrosis, patients with mild fibrosis (stage F1) had significantly higher levels of secondary BAs, and increased diastolic blood pressure (DBP), alanine aminotransferase (ALT), body mass index, and waist circumstance (WC). The combination of serum BAs with WC, DBP, ALT, or Homeostatic Model Assessment for Insulin Resistance performed well in identifying mild fibrosis, in men and women, and in those with/without obesity, with AUROCs 0.80, 0.88, 0.75 and 0.78 in the training set (n = 385), and 0.69, 0.80, 0.61 and 0.69 in the testing set (n = 165), respectively. In comparison, the combination of BAs and clinical/biochemical biomarkers performed less well in identifying significant fibrosis (F2-4). In women and in non-obese subjects, AUROCs were 0.75 and 0.71 in the training set, 0.65 and 0.66 in the validation set, respectively. However, these AUROCs were higher than those observed for the fibrosis-4 index, NAFLD fibrosis score, and Hepamet fibrosis score.ConclusionsSecondary BA levels were significantly increased in NAFLD, especially in those with mild fibrosis. The combination of serum BAs and clinical/biochemical biomarkers for identifying mild fibrosis merits further assessment.

Published
2023

9. Global burden of disease attributable to metabolic risk factors in adolescents and young adults aged 15–39, 1990–2021

Author

Zhou, Xiao-Dong, Chen, Qin-Fen, Targher, Giovanni, Byrne, Christopher D., Mantzoros, Christos S., Zhang, Huijie, Lonardo, Amedeo, Lip, Gregory Y.H., Porta, Gilda, Misra, Anoop, Robertson, Andrew Gerard, Luo, Fei, Alisi, Anna, Yang, Wah, El-Shabrawi, Mortada, Al Momani, Hazem, Somers, Virend K., Katsouras, Christos S., Méndez-Sánchez, Nahum, Lefere, Sander, Szepietowski, Olivia, Sung, Ki-Chul, Hui Ng, Nicholas Beng, Valenti, Luca, Lee, Way Seah, Pik-Shan Kong, Alice, Kızılkaya, Mehmet Celal, Ocama, Ponsiano, Ali, Arshad, Viveiros, Octavio, Ryan, John D., Toro-Huamanchumo, Carlos Jesus, Perera, Nilanka, Ataya, Karim, Yen Kok, Kenneth Yuh, Gracia-Sancho, Jordi, Sharara, Ala I., Prasad, Arun, Oviedo, Rodolfo J., Ospanov, Oral, Ruiz-Úcar, Elena, Alswat, Khalid, Abbas, Syed Imran, Abdelbaki, Tamer N., Wong, Yu Jun, Fouad, Yasser, Shapiro, Michael D., Bacopoulou, Flora, Sookoian, Silvia, Kehar, Mohit, Chan, Wah-Kheong, Treeprasertsuk, Sombat, Adams, Leon, Turan, Serap, Zuluaga, Mauricio, Pirola, Carlos Jose, Thaher, Omar, Molina, Gabriel Alejandro, Jumaev, Nozim Adxamovich, Al-Busafi, Said A., Opio, Christopher K., Lim-Loo, Michelle Ching, Adithya Lesmana, Cosmas Rinaldi, Kamani, Lubna, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

10. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus

Author

Zeng, Xu-Fen, Varady, Krista A., Wang, Xiang-Dong, Targher, Giovanni, Byrne, Christopher D., Tayyem, Reema, Latella, Giovanni, Bergheim, Ina, Valenzuela, Rodrigo, George, Jacob, Newberry, Carolyn, Zheng, Ju-Sheng, George, Elena S., Spearman, C. Wendy, Kontogianni, Meropi D., Ristic-Medic, Danijela, Peres, Wilza Arantes Ferreira, Depboylu, Gamze Yurtdaş, Yang, Wanshui, Chen, Xu, Rosqvist, Fredrik, Mantzoros, Christos S., Valenti, Luca, Yki-Järvinen, Hannele, Mosca, Antonella, Sookoian, Silvia, Misra, Anoop, Yilmaz, Yusuf, Kim, Won, Fouad, Yasser, Sebastiani, Giada, Wong, Vincent Wai-Sun, Åberg, Fredrik, Wong, Yu Jun, Zhang, Pianhong, Bermúdez-Silva, Francisco-Javier, Ni, Yan, Lupsor-Platon, Monica, Chan, Wah Kheong, Méndez-Sánchez, Nahum, de Knegt, Robert J., Alam, Shahinul, Treeprasertsuk, Sombat, Wang, Li, Du, Mulong, Zhang, Tiejun, Yu, Ming-Lung, Zhang, Huijie, Qi, Xingshun, Liu, Xin, Pinyopornpanish, Kanokwan, Fan, Yu-Chen, Niu, Kaijun, Jimenez-Chillaron, Josep C., and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

11. Global burden of metabolic diseases, 1990–2021

Author

Zhang, Huai, Zhou, Xiao-Dong, Shapiro, Michael D., Lip, Gregory Y.H., Tilg, Herbert, Valenti, Luca, Somers, Virend K., Byrne, Christopher D., Targher, Giovanni, Yang, Wah, Viveiros, Octavio, Opio, Christopher Kenneth, Mantzoros, Christos S., Ryan, John D., Kok, Kenneth Yuh Yen, Jumaev, Nozim Adxamovich, Perera, Nilanka, Robertson, Andrew Gerard, Abu-Abeid, Adam, Misra, Anoop, Wong, Yu Jun, Ruiz-Úcar, Elena, Ospanov, Oral, Kızılkaya, Mehmet Celal, Luo, Fei, Méndez-Sánchez, Nahum, Zuluaga, Mauricio, Lonardo, Amedeo, Al Momani, Hazem, Toro-Huamanchumo, Carlos Jesus, Adams, Leon, Al-Busafi, Said A., Sharara, Ala I., Chan, Wah-Kheong, Abbas, Syed Imran, Sookoian, Silvia, Treeprasertsuk, Sombat, Ocama, Ponsiano, Alswat, Khalid, Kong, Alice Pik-Shan, Ataya, Karim, Lim-Loo, Michelle Ching, Oviedo, Rodolfo J., Szepietowski, Olivia, Fouad, Yasser, Zhang, Huijie, Abdelbaki, Tamer N., Katsouras, Christos S., Prasad, Arun, Thaher, Omar, Ali, Arshad, Molina, Gabriel Alejandro, Sung, Ki-Chul, Chen, Qin-Fen, Lesmana, Cosmas Rinaldi Adithya, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

12. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021

Author

Zhou, Xiao-Dong, Chen, Qin-Fen, Yang, Wah, Zuluaga, Mauricio, Targher, Giovanni, Byrne, Christopher D., Valenti, Luca, Luo, Fei, Katsouras, Christos S., Thaher, Omar, Misra, Anoop, Ataya, Karim, Oviedo, Rodolfo J., Pik-Shan Kong, Alice, Alswat, Khalid, Lonardo, Amedeo, Wong, Yu Jun, Abu-Abeid, Adam, Al Momani, Hazem, Ali, Arshad, Molina, Gabriel Alejandro, Szepietowski, Olivia, Jumaev, Nozim Adxamovich, Kızılkaya, Mehmet Celal, Viveiros, Octavio, Toro-Huamanchumo, Carlos Jesus, Yen Kok, Kenneth Yuh, Ospanov, Oral, Abbas, Syed Imran, Robertson, Andrew Gerard, Fouad, Yasser, Mantzoros, Christos S., Zhang, Huijie, Méndez-Sánchez, Nahum, Sookoian, Silvia, Chan, Wah-Kheong, Treeprasertsuk, Sombat, Adams, Leon, Ocama, Ponsiano, Ryan, John D., Perera, Nilanka, Sharara, Ala I., Al-Busafi, Said A., Opio, Christopher Kenneth, Garcia, Manuel, Lim-Loo, Michelle Ching, Ruiz-Úcar, Elena, Prasad, Arun, Casajoana, Anna, Abdelbaki, Tamer N., and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

16. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Author

Zhou, Xiao-Dong, Targher, Giovanni, Byrne, Christopher D., Somers, Virend, Kim, Seung Up, Chahal, C. Anwar A., Wong, Vincent Wai-Sun, Cai, Jingjing, Shapiro, Michael D., Eslam, Mohammed, Steg, Philippe Gabriel, Sung, Ki-Chul, Misra, Anoop, Li, Jian-Jun, Brotons, Carlos, Huang, Yuli, Papatheodoridis, George V., Sun, Aijun, Yilmaz, Yusuf, Chan, Wah Kheong, Huang, Hui, Méndez-Sánchez, Nahum, Alqahtani, Saleh A., Cortez-Pinto, Helena, Lip, Gregory Y. H., de Knegt, Robert J., Ocama, Ponsiano, Romero-Gomez, Manuel, Fudim, Marat, Sebastiani, Giada, Son, Jang Won, Ryan, John D., Ikonomidis, Ignatios, Treeprasertsuk, Sombat, Pastori, Daniele, Lupsor-Platon, Monica, Tilg, Herbert, Ghazinyan, Hasmik, Boursier, Jerome, Hamaguchi, Masahide, Nguyen, Mindie H., Fan, Jian-Gao, Goh, George Boon-Bee, Al Mahtab, Mamun, Hamid, Saeed, Perera, Nilanka, George, Jacob, and Zheng, Ming-Hua

Published
2023
Full Text
View/download PDF

17. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease

Author

Zhang, Le, El-Shabrawi, Mortada, Baur, Louise A., Byrne, Christopher D., Targher, Giovanni, Kehar, Mohit, Porta, Gilda, Lee, Way Seah, Lefere, Sander, Turan, Serap, Alisi, Anna, Weiss, Ram, Faienza, Maria Felicia, Ashraf, Ambika, Sundaram, Shikha S., Srivastava, Anshu, De Bruyne, Ruth, Kang, Yunkoo, Bacopoulou, Flora, Zhou, Yong-Hai, Darma, Andy, Lupsor-Platon, Monica, Hamaguchi, Masahide, Misra, Anoop, Méndez-Sánchez, Nahum, Ng, Nicholas Beng Hui, Marcus, Claude, Staiano, Amanda E., Waheed, Nadia, Alqahtani, Saleh A., Giannini, Cosimo, Ocama, Ponsiano, Nguyen, Mindie H., Arias-Loste, Maria Teresa, Ahmed, Mohamed Rabea, Sebastiani, Giada, Poovorawan, Yong, Al Mahtab, Mamun, Pericàs, Juan M., Reverbel da Silveira, Themis, Hegyi, Peter, Azaz, Amer, Isa, Hasan M., Lertudomphonwanit, Chatmanee, Farrag, Mona Issa, Nugud, Ahmed Abd Alwahab, Du, Hong-Wei, Qi, Ke-Min, Mouane, Nezha, Cheng, Xin-Ran, Al Lawati, Tawfiq, Fagundes, Eleonora D.T., Ghazinyan, Hasmik, Hadjipanayis, Adamos, Fan, Jian-Gao, Gimiga, Nicoleta, Kamal, Naglaa M., Ștefănescu, Gabriela, Hong, Li, Diaconescu, Smaranda, Li, Ming, George, Jacob, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

19. Global burden of metabolic dysfunction-associated liver disease, 2010 to 2021

Author

Feng, Gong, Targher, Giovanni, Byrne, Christopher D., Yilmaz, Yusuf, Wai-Sun Wong, Vincent, Adithya Lesmana, Cosmas Rinaldi, Adams, Leon A., Boursier, Jerome, Papatheodoridis, Georgios, El-Kassas, Mohamed, Méndez-Sánchez, Nahum, Sookoian, Silvia, Castera, Laurent, Chan, Wah-Kheong, Ye, Feng, Treeprasertsuk, Sombat, Cortez-Pinto, Helena, Yu, Hon Ho, Kim, Won, Romero-Gomez, Manuel, Nakajima, Atsushi, Win, Khin Maung, Kim, Seung Up, Holleboom, Adriaan G., Sebastiani, Giada, Ocama, Ponsiano, Ryan, John D., Lupșor-Platon, Monica, Ghazinyan, Hasmik, Al-Mahtab, Mamun, Hamid, Saeed, Perera, Nilanka, Alswat, Khalid, Pan, Qiuwei, Long, Michelle T., Isakov, Vasily, Mi, Man, Arrese, Marco, Sanyal, Arun, Sarin, Shiv Kumar, Leite, Nathalie Carvalho, Valenti, Luca, Newsome, Philip N., Hagström, Hannes, Petta, Salvatore, Yki-Jarvinen, Hannele, Schattenberg, Jörn M., Castellanos Fernández, Marlen I., Leclercq, Isabelle, Aghayeva, Gulnara, Elzouki, Abdel-Naser, Tumi, Ali, Sharara, Ala I., Labidi, Asma, Sanai, Faisal M., Matar, Khaled, Al-Mattooq, Maen, Akroush, Maisam Waid, Benazzouz, Mustapha, Debzi, Nabil, Alkhatry, Maryam, Barakat, Salma, Al-Busafi, Said A., Rwegasha, John, Yang, Wah, Adwoa, Agyei, Opio, Christopher Kenneth, Sotoudeheian, Mohammadjavad, Wong, Yu Jun, George, Jacob, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

21. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Author

Rinella, Mary E., Lazarus, Jeffrey V., Ratziu, Vlad, Francque, Sven M., Sanyal, Arun J., Kanwal, Fasiha, Romero, Diana, Abdelmalek, Manal F., Anstee, Quentin M., Arab, Juan Pablo, Arrese, Marco, Bataller, Ramon, Beuers, Ulrich, Boursier, Jerome, Bugianesi, Elisabetta, Byrne, Christopher D., Narro, Graciela E. Castro, Chowdhury, Abhijit, Cortez-Pinto, Helena, Cryer, Donna R., Cusi, Kenneth, El-Kassas, Mohamed, Klein, Samuel, Eskridge, Wayne, Fan, Jiangao, Gawrieh, Samer, Guy, Cynthia D., Harrison, Stephen A., Kim, Seung Up, Koot, Bart G., Korenjak, Marko, Kowdley, Kris V., Lacaille, Florence, Loomba, Rohit, Mitchell-Thain, Robert, Morgan, Timothy R., Powell, Elisabeth E., Roden, Michael, Romero-Gómez, Manuel, Silva, Marcelo, Singh, Shivaram Prasad, Sookoian, Silvia C., Spearman, C. Wendy, Tiniakos, Dina, Valenti, Luca, Vos, Miriam B., Wong, Vincent Wai-Sun, Xanthakos, Stavra, Yilmaz, Yusuf, Younossi, Zobair, Hobbs, Ansley, Villota-Rivas, Marcela, and Newsome, Philip N.

Published
2024
Full Text
View/download PDF

22. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

Author

Feng, Gong, Mózes, Ferenc E., Ji, Dong, Treeprasertsuk, Sombat, Okanoue, Takeshi, Shima, Toshihide, Liang, Huiqing, Tsochatzis, Emmanuel, Chen, Jinjun, Schattenberg, Jörn M., Labenz, Christian, Mahadeva, Sanjiv, Chan, Wah Kheong, Chi, Xiaoling, Delamarre, Adèle, de Lédinghen, Victor, Petta, Salvatore, Bugianesi, Elisabetta, Hagström, Hannes, Boursier, Jérôme, Calleja, José Luis, Goh, George Boon-Bee, Gallego-Durán, Rocio, Sanyal, Arun J., Fan, Jian-Gao, Castéra, Laurent, Lai, Michelle, Harrison, Stephen A., Romero-Gomez, Manuel, Kim, Seung Up, Zhu, Yongfen, Ooi, Geraldine, Shi, Junping, Yoneda, Masato, Nakajima, Atsushi, Zhang, Jing, Lupsor-Platon, Monica, Zhong, Bihui, Cobbold, Jeremy F.L., Ye, Chun-Yan, Eddowes, Peter J., Newsome, Philip, Li, Jie, George, Jacob, He, Fangping, Song, Myeong Jun, Tang, Hong, Fan, Yuchen, Jia, Jidong, Xu, Liang, Lin, Su, Li, Yiling, Lu, Zhonghua, Nan, Yuemin, Niu, Junqi, Yan, Xuebing, Zhou, Yongjian, Liu, Chenghai, Deng, Hong, Ye, Qing, Zeng, Qing-Lei, Li, Lei, Wang, Jing, Yang, Song, Lin, Huapeng, Lee, Hye Won, Yip, Terry Cheuk-Fung, Fournier-Poizat, Céline, Wong, Grace Lai-Hung, Pennisi, Grazia, Armandi, Angelo, Liu, Wen-Yue, Shang, Ying, de Saint-Loup, Marc, Llop, Elba, Teh, Kevin Kim Jun, Lara-Romero, Carmen, Asgharpour, Amon, Mahgoub, Sara, Chan, Mandy Sau-Wai, Canivet, Clemence M., Ji, Fanpu, Xin, Yongning, Chai, Jin, Dong, Zhiyong, Targher, Giovanni, Byrne, Christopher D., He, Na, Mi, Man, Ye, Feng, Wong, Vincent Wai-Sun, Pavlides, Michael, and Zheng, Ming-Hua

Published
2024
Full Text
View/download PDF

24. Basal and post-stress ceramide-based risk score CERT1 predicts all-cause mortality and nonfatal myocardial infarction in patients with suspected or established coronary artery disease undergoing stress myocardial perfusion scintigraphy

Author

Mantovani, Alessandro, Molinero, Agustin E., Bonapace, Stefano, Lunardi, Gianluigi, Salgarello, Matteo, Morandin, Riccardo, Moretta, Francesca, Conti, Antonio, Molon, Giulio, Laaksonen, Reijo, Byrne, Christopher D., and Targher, Giovanni

Published
2024
Full Text
View/download PDF

25. Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

Author

Hagström, Hannes, Adams, Leon A, Allen, Alina M, Byrne, Christopher D, Chang, Yoosoo, Grønbæk, Henning, Ismail, Mona, Jepsen, Peter, Kanwal, Fasiha, Kramer, Jennifer, Lazarus, Jeffrey V, Long, Michelle T, Loomba, Rohit, Newsome, Philip N, Rowe, Ian A, Ryu, Seungho, Schattenberg, Jörn M, Serper, Marina, Sheron, Nick, Simon, Tracey G, Tapper, Elliot B, Wild, Sarah, Wong, Vincent Wai‐Sun, Yilmaz, Yusuf, Zelber‐Sagi, Shira, and Åberg, Fredrik

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Immunology, Patient Safety, Good Health and Well Being, Biomedical Research, Clinical Coding, Consensus, Electronic Health Records, Humans, Non-alcoholic Fatty Liver Disease, Reference Standards, Medical Biochemistry and Metabolomics, Gastroenterology & Hepatology, Clinical sciences
Abstract

Background and aimsElectronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in NAFLD, where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Diseases (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.Approach and resultsResearchers with an interest in EHR-based NAFLD research were invited to collectively define which administrative codes are most appropriate for documenting exposures and outcomes. We used a modified Delphi approach to reach consensus on several commonly encountered methodological challenges in the field. After two rounds of revision, a high level of agreement (>67%) was reached on all items considered. Full consensus was achieved on a comprehensive list of administrative codes to be considered for inclusion and exclusion criteria in defining exposures and outcomes in EHR-based NAFLD research. We also provide suggestions on how to approach commonly encountered methodological issues and identify areas for future research.ConclusionsThis expert panel consensus statement can help harmonize and improve generalizability of EHR-based NAFLD research.

Published
2021

26. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

Author

Cariou, Bertrand, Byrne, Christopher D, Loomba, Rohit, and Sanyal, Arun J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Women's Health, Diabetes, Hepatitis, Prevention, Nutrition, Obesity, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, 2.1 Biological and endogenous factors, Metabolic and endocrine, Oral and gastrointestinal, Good Health and Well Being, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Liver, Non-alcoholic Fatty Liver Disease, Sodium-Glucose Transporter 2 Inhibitors, fatty liver disease, GLP&#8208, 1, insulin resistance, pharmaco&#8208, epidemiology, type 2 diabetes, GLP-1, pharmaco-epidemiology, Endocrinology & Metabolism, Clinical sciences
Abstract

AimsTo conduct a systematic literature review to identify recent epidemiological, biomarker, genetic and clinical evidence that expands our understanding of nonalcoholic fatty liver disease (NAFLD) as a metabolic disorder.Materials and methodsWe performed a literature search using PubMed to identify trials, observational studies and meta-analyses published in the past 5 years.ResultsA total of 95 publications met prespecified inclusion criteria and reported on the interplay between NAFLD/nonalcoholic steatohepatitis (NASH) and metabolic dysfunction, in terms of disease burden and/or epidemiology (n = 10), pathophysiology, risk factors and associated conditions (n = 29), diagnosis and biomarkers (n = 34), and treatment approaches (n = 22). There is a growing body of evidence on the links between NAFLD/NASH pathogenesis and mechanisms of metabolic dysfunction, through liver lipid accumulation, insulin resistance, inflammation, apoptosis, and fibrogenic remodelling within the liver. The frequent co-occurrence of NAFLD with obesity, metabolic syndrome and type 2 diabetes supports this premise. Therapeutic approaches originally envisaged for type 2 diabetes or obesity (such as glucagon-like peptide-1 receptor agonists, sodium-glucose co-transporter-2 inhibitors, insulin sensitizers and bariatric surgery) have shown promising signs of benefit for patients with NAFLD/NASH.ConclusionsGiven the complex interplay between NAFLD and metabolic dysfunction, there is an urgent need for multidisciplinary collaboration and established protocols for care of patients with NAFLD that are individualized and ideally support reduction of overall metabolic risk as well as treatment for NASH.

Published
2021

28. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD

Author

Tang, Liang-Jie, Li, Gang, Eslam, Mohammed, Zhu, Pei-Wu, Chen, Sui-Dan, Leung, Howard Ho-Wai, Huang, Ou-Yang, Wong, Grace Lai-Hung, Zhou, Yu-Jie, Karsdal, Morten, Leeming, Diana Julie, Jiang, Pei, Wang, Cong, Yuan, Hai-Yang, Byrne, Christopher D., Targher, Giovanni, George, Jacob, Wong, Vincent Wai-Sun, and Zheng, Ming-Hua

Published
2023
Full Text
View/download PDF

43. MASLD Is Associated With an Increased Long‐Term Risk of Atrial Fibrillation: An Updated Systematic Review and Meta‐Analysis.

Author

Mantovani, Alessandro, Morandin, Riccardo, Sani, Elena, Fiorio, Veronica, Shtembari, Emigela, Bonapace, Stefano, Petta, Salvatore, Polyzos, Stergios A., Byrne, Christopher D., and Targher, Giovanni

Subjects
FATTY liver, HEPATIC fibrosis, NOSOLOGY, ATRIAL arrhythmias, ATRIAL fibrillation, PUBLICATION bias
Abstract

Background: Studies have reported an association between metabolic dysfunction‐associated steatotic liver disease (MASLD) and an increased risk of developing atrial fibrillation (AF). However, the magnitude of the risk and whether this risk varies with the severity of MASLD remains uncertain. Methods: In this systematic review and meta‐analysis, we searched three large electronic databases using predefined keywords to identify cohort studies (published up to 30 September 2024) in which MASLD was diagnosed by liver biopsy, imaging methods, International Classification of Diseases (ICD) codes, or blood‐based scores. The primary outcome was the occurrence of AF based on ICD codes, medical records, or electrocardiograms. Meta‐analysis was performed using random‐effects modelling. Results: We identified 16 retrospective cohort studies with aggregate data on ~19.5 million individuals followed for a median of 7.2 years. MASLD was significantly associated with an increased risk of developing incident AF (random‐effects hazard ratio 1.20, 95% CI 1.10–1.32; I2 = 92%). This risk did not appear to further increase with the severity of liver fibrosis (n = 3 studies; random‐effects hazard ratio 1.22, 95% CI 1.18–1.26; I2 = 10%). The risk of AF remained significant even after adjusting for age, sex, body mass index, hypertension, Type 2 diabetes or other cardiometabolic risk factors. Sensitivity analyses did not modify these findings. The funnel plot and Egger's test showed no significant publication bias. Conclusions: This updated and comprehensive meta‐analysis provides evidence that MASLD is significantly associated with an increased long‐term risk of developing incident AF. Further research is required to better decipher the link between MASLD and increased AF incidence. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

44. Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study.

Author

Yuan, Hai‐Yang, Liu, Wen‐Yue, Feng, Gong, Chen, Sui‐Dan, Jin, Xin‐Zhe, Chen, Li‐Li, Song, Zi‐Jun, Li, Ke, Byrne, Christopher D., Targher, Giovanni, Tian, Na, Li, Gang, Zhang, Xin‐Lei, George, Jacob, Zhou, Meng, Wang, Fudi, and Zheng, Ming‐Hua

Subjects
FATTY liver, HEPATIC fibrosis, SINGLE nucleotide polymorphisms, LIVER diseases, HEPATITIS
Abstract

Aims: To explore the associations between cuprotosis‐related genes (CRGs) across different stages of liver disease in metabolic dysfunction‐associated fatty liver disease (MAFLD), including hepatocellular carcinoma (HCC). Materials and Methods: We analysed several bulk RNA sequencing datasets from patients with MAFLD (n = 331) and MAFLD‐related HCC (n = 271) and two MAFLD single‐cell RNA sequencing datasets. To investigate the associations between CRGs and MAFLD, we performed differential correlation, logistic regression and functional enrichment analyses. We also validated the findings in an independent Wenzhou PERSONS cohort of MAFLD patients (n = 656) used for a genome‐wide association study (GWAS). Results: GLS, GCSH and ATP7B genes showed significant differences across the MAFLD spectrum and were significantly associated with liver fibrosis stages. GLS was closely associated with fibrosis stages in patients with MAFLD and those with MAFLD‐related HCC. GLS is predominantly expressed in monocytes and T cells in MAFLD. During the progression of metabolic dysfunction‐associated fatty liver to metabolic‐associated steatohepatitis, GLS expression in T cells decreased. GWAS revealed that multiple single nucleotide polymorphisms in GLS were associated with clinical indicators of MAFLD. Conclusions: GLS may contribute to liver inflammation and fibrosis in MAFLD mainly through cuprotosis and T‐cell activation, promoting the progression of MAFLD to HCC. These findings suggest that cuprotosis may play a role in MAFLD progression, potentially providing new insights into MAFLD pathogenesis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis.

Author

Feng, Gong, He, Na, Gao, Jing, Li, Xiao‐Cheng, Zhang, Fen‐Na, Liu, Cheng‐Cheng, Targher, Giovanni, Byrne, Christopher D., Mi, Man, Zheng, Ming‐Hua, and Ye, Feng

Subjects
LOCUS (Genetics), FATTY liver, RECEIVER operating characteristic curves, BIOMARKERS, ODDS ratio, MENDELIAN randomization
Abstract

Aim: Non‐invasive diagnostics for metabolic dysfunction–associated fatty liver disease (MAFLD) remain challenging. We aimed to identify novel key genes as non‐invasive biomarkers for MAFLD, elucidate causal relationships between biomarkers and MAFLD and determine the role of immune cells as potential mediators. Materials and Methods: Utilizing published transcriptome data of patients with biopsy‐proven MAFLD, we applied linear models for microarray data, least absolute shrinkage and selector operation (LASSO) regressions and receiver operating characteristic (ROC) curve analyses to identify and validate biomarkers for MAFLD. Using the expression quantitative trait loci database and a cohort of 778 614 Europeans, we used Mendelian randomization to analyse the causal relationships between key biomarkers and MAFLD. Additionally, mediation analysis was performed to examine the involvement of 731 immunophenotypes in these relationships. Results: We identified 31 differentially expressed genes, and LASSO regression showed three hub genes, IGFBP2, PEG10, and P4HA1, with area under the receiver operating characteristic (AUROC) curve of 0.807, 0.772 and 0.791, respectively, for identifying MAFLD. The model of these three genes had an AUROC of 0.959 and 0.800 in the development and validation data sets, respectively. This model was also validated using serum‐based enzyme‐linked immunosorbent assay data from MAFLD patients and control subjects (AUROC: 0.819, 95% confidence interval: 0.736–0.902). PEG10 was associated with an increased MAFLD risk (odds ratio = 1.106, p = 0.032) via inverse variance–weighted analysis, and about 30% of this risk was mediated by the percentage of CD11c + CD62L– monocytes. Conclusions: The MAFLD panels have good diagnostic accuracy, and the causal link between PEG10 and MAFLD was mediated by the percentage of CD11c + CD62L– monocytes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

46. Body Composition and Metabolism in Adults With Molecularly Confirmed Silver-Russell Syndrome.

Author

Lokulo-Sodipe, Oluwakemi, Inskip, Hazel M, Byrne, Christopher D, Child, Jenny, Wakeling, Emma L, Mackay, Deborah J G, Temple, I Karen, and Davies, Justin H

Subjects
BONE density, BODY mass index, LOW birth weight, ADIPOSE tissues, MEDIAN (Mathematics)
Abstract

Context Low birth weight, as seen in Silver-Russell syndrome (SRS), is associated with later cardiometabolic disease. Data on long-term outcomes and adult body composition in SRS are limited. Objective To evaluate body composition and metabolic health in adults with SRS. Methods This was an observational study of 25 individuals with molecularly confirmed SRS, aged ≥ 18 years, from research facilities across the UK. Body composition and metabolic health were assessed at a single appointment. Individuals with SRS were compared with unaffected men and women (from the Southampton Women's Survey [SWS]). Fat mass, lean mass, bone mineral density (BMD), blood pressure, lipids, and blood glucose were measured. Results Twenty-five adults with SRS were included (52% female). The median age was 32.9 years (range, 22.0 to 69.7). Fat percentage was greater in the SRS group than the SWS cohort (44.1% vs 30.3%, P <.001). Fat mass index was similar (9.6 vs 7.8, P =.3). Lean mass percentage (51.8% vs 66.2%, P <.001) and lean mass index (13.5 kg/m2 vs 17.3 kg/m2, P <.001) were lower in the SRS group than the SWS cohort. BMD was lower in the SRS group than the SWS cohort (1.08 vs 1.24, P <.001; all median values). Total cholesterol was ≥ 5 mmol/L in 52.0%. Triglyceride levels were ≥ 1.7 mmol/L in 20.8%. Fasting blood glucose levels were ≥ 6.1 mmol/L in 25.0%. Hypertension was present in 33.3%. Conclusion Adults with SRS have an unfavorable body composition and predisposition to cardiometabolic disease. These results support the need for a health surveillance strategy to mitigate adverse outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD

Author

Tang, Liang-Jie, Ma, Hong-Lei, Eslam, Mohammed, Wong, Grace Lai-Hung, Zhu, Pei-Wu, Chen, Sui-Dan, Leeming, Diana Julie, Karsdal, Morten, Li, Gang, Huang, Ou-Yang, Leung, Howard Ho-Wai, Zhou, Yu-Jie, Feng, Qian, Jiang, Pei, Gao, Li-Mei, Byrne, Christopher D., Targher, Giovanni, George, Jacob, Wong, Vincent Wai-Sun, and Zheng, Ming-Hua

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results